Work

Effectiveness and safety of tenofovir alafenamide in chronic hepatitis B patients over 30 years old with positive hepatitis B virus DNA: a double-center retrospective study

Year: 2025

Type: article

Abstract: Aims: The aim of this study was to evaluate the effectiveness and safety of Tenofovir Alafenamide (TAF) in chronic hepatitis B (CHB) patients, particularly those aged 30-35 years or with baseline normal alanine aminotransferase (ALT) levels. Methods: A total of 191 patients were recruited, and their data were collected from two hospital in China from January 2017 to March 2023. Liver function and HBV-related indicators were measured at baseline, 48-week, and 96-week. The safety and effectiveness of TAF were evaluated in the high-age group (> 35 years) and the low-age group (30-35 years), as well as in the ALT-normal group (ALT < 1 × ULN) and the ALT-elevated (ALT ≥ 1 × ULN) group. Results: TAF treatment for 48 weeks or 96 weeks could significantly improve the progression of hepatitis as evidenced by lower ALT, AST, and HBV DNA. TAF is still effective for patients aged 30-35 or those with normal ALT levels. Additionally, for CHB patients with baseline chronic kidney disease staging at stage 2 or below, 1-2 years of TAF treatment has minimal impact on their renal function. Conclusion: TAF treatment significantly alleviated the progression of CHB patients over a 96-week follow-up period. TAF remains effective for younger patients or those with normal liver function, providing evidence for further expanding antiviral indications.

Source: Frontiers in Medicine

DOI: 10.3389/fmed.2025.1680839

Authors: Yinong Feng, Li Zhou, Shaoyuan Shi, Zehong Wang, Xuanxuan Wang, Fan Du

Institutions: Wuhan Union Hospital, Huazhong University of Science and Technology

Language: English

Topic: Hepatitis B Virus Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801